Edition:
United States

Thermo Fisher Scientific Inc (TMO.N)

TMO.N on New York Stock Exchange

154.65USD
4:01pm EDT
Change (% chg)

$-0.68 (-0.44%)
Prev Close
$155.33
Open
$155.30
Day's High
$155.90
Day's Low
$154.03
Volume
441,161
Avg. Vol
481,687
52-wk High
$161.61
52-wk Low
$137.61

Latest Key Developments (Source: Significant Developments)

Thermo Fisher Scientific and Cell And Gene Therapy Catapult collaborate
Tuesday, 21 Mar 2017 08:27am EDT 

Thermo Fisher Scientific Inc :Thermo Fisher Scientific Inc - co and Cell And Gene Therapy Catapult collaborate to optimise advanced therapy supply chain.  Full Article

Thermo Fisher issues 500 mln euro of certain senior notes due 2027
Thursday, 16 Mar 2017 06:58am EDT 

Thermo Fisher Scientific Inc : On March 16, 2017, issued EUR 500 million aggregate principal amount of 1.450 pct senior notes due 2027 . Notes will mature on March 16, 2027 - SEC filing .Interest on notes will accrue at rate of 1.450 percent per annum.  Full Article

Thermo Fisher Scientific prices offering of Euro-denominated senior notes
Tuesday, 7 Mar 2017 05:05pm EST 

Thermo Fisher Scientific Inc : Thermo Fisher Scientific prices offering of euro-denominated senior notes . Thermo Fisher Scientific - priced offering of eur500 million of 1.450% senior notes due 2027 at an issue price of 98.824% of principal amount .Notes will pay interest on an annual basis.  Full Article

Thermo Fisher Scientific elects new director to board
Wednesday, 1 Mar 2017 09:00am EST 

Thermo Fisher Scientific Inc : Thermo Fisher Scientific elects new director to board . Thermo Fisher Scientific Inc says has elected Dion Weisler to its board of directors .Thermo Fisher Scientific Inc says Weisler's appointment brings total number of Thermo Fisher board members to 12.  Full Article

Achaogen Inc says strategic milestone achieved in TDM Assay development
Wednesday, 22 Feb 2017 04:01pm EST 

Achaogen Inc : Achaogen Inc says strategic milestone achieved in TDM Assay development . Achaogen Inc says Thermo Fisher Scientific to develop and then commercialize its assay for measuring concentration of plazomicin . Achaogen Inc says achieved a strategic milestone in their ongoing efforts to develop an assay enabling therapeutic drug management of plazomicin . Plans to submit a new drug application (NDA) for plazomicin to Food and Drug Administration (FDA) in second half of 2017 .Says also plans to submit a marketing authorization application (MAA) to European Medicines Agency (EMA) in 2018.  Full Article

Asuragen enters into collaboration deal with Thermo Fisher
Monday, 20 Feb 2017 09:00am EST 

:Asuragen Inc - Entered collaboration deal with Thermo Fisher scientific for development, commercialization of capillary electrophoresis-based in vitro diagnostics.  Full Article

Thermo Fisher Scientific sees FY'17 adj EPS bewteen $9.06 - $9.24 - Conf call
Tuesday, 31 Jan 2017 09:50am EST 

Thermo Fisher Scientific Inc : Thermo Fisher Scientific Inc sees FY 2017 revenue between $19.38 billion to $19.62 billion - Conf call . FY2017 revenue view $19.50 billion -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted EPS in range of $9.06 to $9.24 - Conf call . FY2017 earnings per share view $9.08 -- Thomson Reuters I/B/E/S . Sees FY 2017 organic revenue growth of 4 percent - Conf call . Says assuming foreign exchange is a $300 million revenue headwind for 2017 - Conf call . Says assuming net capital expenditures to be about $500 million for 2017 - Conf call . Says 2017 guidance also assumes total of $750 million of share buybacks in 2017 - Conf call Further company coverage: [TMO.N] ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

Thermo Fisher Scientific reports Q4 GAAP EPS of $1.59
Tuesday, 31 Jan 2017 06:00am EST 

Thermo Fisher Scientific Inc : Q4 GAAP earnings per share $1.59 . Q4 adjusted earnings per share $2.41 . Q4 revenue increased 6 percent to $4.95 billion .Q4 Life Sciences Solutions segment revenue grew 10 percent to $1.34 billion.  Full Article

Singulex, Thermo Fisher enter into license, supply agreement
Thursday, 8 Dec 2016 09:00am EST 

Singulex Inc : Agreement provides Singulex access to Thermo Scientific BRAHMS PCT .Singulex and Thermo Fisher Scientific enter into license and supply agreement to bring next generation immunodiagnostics to sepsis and SIRS Diagnostics.  Full Article

Thermo Fisher Scientific ‍​reports Q3 ‍​GAAP earnings $1.19/share
Thursday, 27 Oct 2016 06:00am EDT 

Thermo Fisher Scientific Inc : ‍​Q3 adjusted earnings per share $2.03 . ‍​Q3 revenue increased 9 percent to $4.49 billion . Q3 ‍​GAAP earnings per share $1.19 . ‍​Raising 2016 revenue, adjusted earnings per share guidance . ‍​Now sees 2016 revenue of $18.25 billion to $18.39 billion, versus previous guidance of $17.84 billion to $18 billion . Sees 2016 earnings per share of $8.19 to $8.30, versus the $8.07 to $8.20 previously announced . Q3 ‍​life sciences solutions segment revenue $1.23 billion, up 14 percent . Q3 earnings per share view $1.97, revenue view $4.39 billion -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $8.21, revenue view $18.12 billion -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Thermo Fisher Scientific and Cell And Gene Therapy Catapult collaborate

* Thermo Fisher Scientific Inc - co and Cell And Gene Therapy Catapult collaborate to optimise advanced therapy supply chain Source text for Eikon: Further company coverage: